Immunotherapy of allergy: anergy, deletion, and immune deviation
about
Genetically engineered and synthetic allergen derivatives: candidates for vaccination against type I allergy.Allergen immunotherapy: current and new therapeutic strategies.Synthesized OVA323-339MAP octamers mitigate OVA-induced airway inflammation by regulating Foxp3 T regulatory cellsInhibition of human T-cell responses by allergen peptides.The future of vaccination as a treatment strategy in dermatological diseases.Genes of tolerance.Mechanisms of allergen specific immunotherapy--T-cell tolerance and more.Regulatory T Cells Contribute to the Inhibition of Radiation-Induced Acute Lung Inflammation via Bee Venom Phospholipase A₂ in Mice.Latex allergy: a model for therapy.The hevein domain of the major latex-glove allergen Hev b 6.01 contains dominant T cell reactive sites.Impaired secretion of interleukin-4 and interleukin-13 by allergen-specific T cells correlates with defective nuclear expression of NF-AT2 and jun B: relevance to immunotherapy.Characterization of the human T cell response to rye grass pollen allergens Lol p 1 and Lol p 5.Hypoallergenic Variant of the Major Egg White Allergen Gal d 1 Produced by Disruption of Cysteine Bridges.Immune response modulation by recombinant peptides expressed in virus-like particles.Efficacy of recombinant adenovirus as vector for allergen gene therapy in a mouse model of type I allergy.Canine atopic dermatitis: a retrospective study of 169 cases examined at the University of California, Davis, 1992-1998. Part II. Response to hyposensitization.Blocking antibodies in allergen immunotherapy: the Yin and Yang.Molecular characterization of human IgG monoclonal antibodies specific for the major birch pollen allergen Bet v 1. Anti-allergen IgG can enhance the anaphylactic reaction.VH gene usage in immunoglobulin E responses of seasonal rhinitis patients allergic to grass pollen is oligoclonal and antigen driven.Amino Acid Substitution in Par j 2 Recombinant Allergen and Its Effect on IgE Binding Capacity
P2860
Q33737248-5D852635-3A59-49B5-B40E-926FBDD035A8Q34074753-0042D8FE-4AD9-4EA5-9FF1-2B949B92257EQ34329409-5DDDB059-93C0-4886-96C1-D487439A65ABQ34567734-34CEE81B-9280-481A-885D-BB6E8C68AB82Q35015879-2BC48A02-30EF-435A-9043-9461ECBAC346Q35855013-6C3463EC-36D6-437C-AB21-54A40ED720ECQ36515366-E5A842BF-1565-4AEA-B33F-9C2854370739Q36946923-0682C32D-198D-4AA8-ADC5-0DF5FCEF0940Q37171082-759396DA-76FB-45C2-8A6F-B35A3E92EE3AQ40567610-5D51A8D6-87F6-4ED8-8948-FFC731E12C2CQ40637631-CA7C9474-A359-442B-8397-F08753DDB7DAQ40685920-D37CC4A4-B62B-4413-8880-93E8DE9F1761Q41812197-CDD295F8-ADAC-40C3-B309-F3081A5DD2B5Q45733509-029C3B42-0F1F-4942-88C3-DFF1B7776C1EQ45883616-2CC551A4-ADAB-4CCE-9306-0086723558F5Q46022919-E4B819F6-1E03-47C9-A5D2-916178CACE82Q47776464-C35D763F-8BEC-4E8D-B1A8-6C3DB47F4499Q47895314-BB7C6246-FFD3-45F2-BBC3-BD179A624203Q47988480-0A381CF6-B924-49E1-87F8-A07C1B31071BQ58647294-4660FC84-5100-47AF-B072-8B32FD0F5161
P2860
Immunotherapy of allergy: anergy, deletion, and immune deviation
description
im Dezember 1998 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 December 1998
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в грудні 1998
@uk
name
Immunotherapy of allergy: anergy, deletion, and immune deviation
@en
Immunotherapy of allergy: anergy, deletion, and immune deviation
@nl
type
label
Immunotherapy of allergy: anergy, deletion, and immune deviation
@en
Immunotherapy of allergy: anergy, deletion, and immune deviation
@nl
prefLabel
Immunotherapy of allergy: anergy, deletion, and immune deviation
@en
Immunotherapy of allergy: anergy, deletion, and immune deviation
@nl
P1476
Immunotherapy of allergy: anergy, deletion, and immune deviation
@en
P2093
P304
P356
10.1016/S0952-7915(98)80082-4
P577
1998-12-01T00:00:00Z